This Bladder Cancer Awareness Month, urologic oncologists at Hackensack University Medical Center are excited to offer a new option for bladder cancers that have continued to grow despite initial ...
Three-year median follow-up update of BGB-A317-2002-IIT: A phase 2 study of neoadjuvant tislelizumab plus gemcitabine and cisplatin in patients with cT2–T4aN0M0 muscle-invasive bladder cancer. This is ...
Bladder cancer is one of the more common cancers worldwide. It is considered a major health care problem with a high financial burden. Of these cases, 75% are non-muscle-invasive, which characterizes ...
Gary Steinberg, MD, highlights the FDA approval of the gemcitabine intravesical system and what this means for patients with BCG-unresponsive NMIBC. For patients with high-risk, BCG-unresponsive ...
Gary Steinberg, MD, discusses the clinical significance of the new FDA-approved gemcitabine intravesical system for BCG-unresponsive NMIBC. For patients with Bacillus Calmette-Guérin ...
This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.
The FDA has approved a gemcitabine intravesical system for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), either with or without ...
The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their ...
Neoadjuvant mitomycin C prior to TURBT reduced recurrence risk by 77%, possibly by preventing free-floating cancer cells dislodged during surgery from reimplanting and by increasing local exposure at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results